Member of Lyonbiopole
PHAXIAM is a biopharmaceutical company developing innovative treatments for resistant bacterial infections, which are responsible for many serious infections. The company is building on an innovative approach based on the use of phages, natural bacterial-killing viruses. PHAXIAM is developing a portfolio of phages targeting 3 of the most resistant and dangerous bacteria, which together account for more than two-thirds of resistant hospital-acquired infections: Staphylococcus aureus, Escherichia coli and Pseudomonas aeruginosa.
PHAXIAM is listed on the Nasdaq Capital Market in the United States (ticker: PHXM) and on the Euronext regulated market in Paris (ISIN code: FR0011471135, ticker: PHXM). PHAXIAM is part of the CAC Healthcare, CAC Pharma & Bio, CAC Mid & Small, CAC All Tradable, EnterNext PEA-PME 150 and Next Biotech indexes.
Strategic application domain: Human Medicine
Application market: Infectious Diseases
Type of activity: Therapeutics, Pharma or Biotech
Technologies: Cell Therapy - Stem cells - Cell Biology - Biobanking, Drug delivery device & Technologies
Created on nov. 15th, 2004 - 70 employees
Address
Bâtiment Bioserra, 60 avenue Rockefeller 69008 LYON
Vous devez être connecté et membre de Lyonbiopôle pour voir les contacts.
